```
ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
L7
ΑN
     2000:345417
                 CAPLUS
     133:146530
DN
     Primary structure of CHH/MIH/GIH-like peptides in sinus gland extracts
ΤI
     from Penaeus vannamei
     Wang, Y. J.; Hayes, T. K.; Holman, G. M.; Chavez, A. R.; Keeley, L. L.
ΑIJ
     Department of Entomology, Texas A&M University, College Station, TX,
CS
     77843-2475, USA
     Peptides (New York) (2000), 21(4), 477-484
SO
     CODEN: PPTDD5; ISSN: 0196-9781
PB
     Elsevier Science Inc.
     Journal
DΤ
     English
LΑ
     6-3 (General Biochemistry)
CC
     Section cross-reference(s): 12
     Peptides belonging to the CHH/MIH/GIH-family of crustacean hormones were
AΒ
     isolated from acetic acid exts. of sinus glands isolated from eyestalks of
     the shrimp, Penaeus vannamei. The peptides were isolated by chromatog.
     and mol. wts. detd. by MALDI mass spectrometry. Peptides in the range of
     7-9 kDa and contg. three disulfide bridges were selected for amino acid
     sequence anal. Three peptides with the requisite properties were present
     in sufficient amts. for sequence anal. Two peptides had unique sequences
     similar to CHH/MIH/GIH peptides from other crustaceans. A third peptide
     seemed to be a truncated form of one of the previous sequences.
     Penaeus sinus gland peptide sequence
ST
TТ
     Proteins, specific or class
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (PK20; primary structure of CHH/MIH/GIH-like peptides in sinus gland
        exts. from Penaeus vannamei)
IT
     Proteins, specific or class
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
       -(PK21; primary structure of CHH/MIH/GIH-like peptides in sinus gland
        exts. from Penaeus vannamei)
     Proteins, specific or class
TΤ
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (PK26; primary structure of CHH/MIH/GIH-like peptides in sinus gland
        exts. from Penaeus vannamei)
IT
     Proteins, specific or class
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (PK27; primary structure of CHH/MIH/GIH-like peptides in sinus gland
        exts. from Penaeus vannamei)
     Proteins, specific or class
ΙT
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (PK28; primary structure of CHH/MIH/GIH-like peptides in sinus gland
        exts. from Penaeus vannamei)
IT
     Penaeus vannamei
     Protein sequences
        (primary structure of CHH/MIH/GIH-like peptides in sinus gland exts.
        from Penaeus vannamei)
IT
     Eyestalk
        (sinus gland; primary structure of CHH/MIH/GIH-like peptides in sinus
        gland exts. from Penaeus vannamei)
IT
                   287417-48-5
                                 287478-97-1
                                               287478-98-2
     287398-39-4
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (amino acid sequence; primary structure of CHH/MIH/GIH-like peptides in
```

sinus gland exts. from Penaeus vannamei)

--

L11 ANSWER 30 OF 36 MEDLINE on STN DUPLICATE 18

AN 93352959 MEDLINE

DN 93352959 PubMed ID: 8349917

TI Essentials of pressure ulcer treatment. The diabetic experience.

AU Miller O F 3rd

CS Department of Dermatology, Geisinger Clinic, Danville, Pennsylvania 17822.

SO JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, (1993 Aug) 19 (8) 759-63.

Journal code: 7707501. ISSN: 0148-0812.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199309

ED Entered STN: 19931001 Last Updated on STN: 19931001

Entered Medline: 19930916

AB BACKGROUND. Diabetes accounts for over half of the lower extremity amputations in the United States. However, ulcers of the diabetic foot can often be treated successfully and amputations avoided.

OBJECTIVE. To review treatment of diabetic foot ulcers. RESULTS. Physicians must recognize the critical clinical and diagnostic features of ischemic and neuropathic ulcers. Therapy is directed towards vascular repair in the ischemic ulcer and relief of weight bearing through casting and shoes with molded insoles in the neuropathic ulcer. Sound principles of wound care apply to all ulcers. CONCLUSION. For successful preventive foot care patients and physicians need to understand how and why ulcers form and the

rationale for the types of footwear and care necessary to prevent ulcers.

```
761
    FILE SCISEARCH
2
    FILE SYNTHLINE
     FILE TOXCENTER
284
479
     FILE USPATFULL
14
     FILE USPAT2
    FILE WPIDS
109
109 FILE WPINDEX
 QUE IMMUNOPHILIN
  SEA IMMUNOPHILIN(P)CYTOPLASM
 _____
 0* FILE ADISNEWS
 0* FILE BIOCOMMERCE
19 FILE BIOSIS
 1* FILE BIOTECHABS
 1* FILE BIOTECHDS
22* FILE BIOTECHNO
 7 FILE CANCERLIT
28 FILE CAPLUS
 0* FILE CEABA-VTB
 0* FILE CIN
     FILE DISSABS
 3
  2
     FILE DDFU
 3
     FILE DRUGU
21
     FILE EMBASE
19*
     FILE ESBIOBASE
 2*
     FILE FEDRIP
 0*
    FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE FSTA
  3
    FILE IFIPAT
  1 FILE JICST-EPLUS
 0* FILE KOSMET
    FILE LIFESCI
11
                     ... . . . . . . . . . .
 0*
    FILE MEDICONF
     FILE MEDLINE
 23
 0* FILE NTIS
  0* FILE NUTRACEUT
  3* FILE PASCAL
 0* FILE PHARMAML
    FILE SCISEARCH
 22
     FILE TOXCENTER
  8
     FILE USPATFULL
     FILE WPIDS
 3 FILE WPINDEX
  QUE IMMUNOPHILIN(P) CYTOPLASM
  SEA L2(P)LYMPHOI?
  ----
  0* FILE ADISNEWS
 0* FILE BIOCOMMERCE
  2 FILE BIOSIS
 0* FILE BIOTECHABS
  0* FILE BIOTECHDS
  1* FILE BIOTECHNO
     FILE CAPLUS
 0* FILE CEABA-VTB
  0* FILE CIN
  2
     FILE EMBASE
  2* FILE ESBIOBASE
```

1* FILE FEDRIP

Ì

L1

L2

- 0* FILE FOMAD
- 0* FILE FOREGE
- 0* FILE FROSTI
- 0* FILE FSTA
- 1 FILE IFIPAT
- 0* FILE KOSMET
- 0* FILE MEDICONF
- 2 FILE MEDLINE
- 0* FILE NTIS
- 0* FILE NUTRACEUT
- 0* FILE PASCAL
- 0* FILE PHARMAML
- 1 FILE SCISEARCH
- 1 FILE USPATFULL
- 1 FILE WPIDS
- 1 FILE WPINDEX

QUE L2(P) LYMPHOI?

L3

L4 7 S L3

L5

L6

<u>L7___</u>

3 DUP REM L4 (4 DUPLICATES REMOVED)

1 S IMMUNOPHILIN (P) CYTOPLASM (P) 8.4

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, ...' ENTERED AT 13:33:40 ON 17 NOV 2003

SEA IMMUNOPHILIN (P) CYTOPLASM (P) 8.4

- 0* FILE ADISNEWS
- 0* FILE BIOCOMMERCE
- 0* FILE BIOTECHABS
- 0* FILE BIOTECHDS
- 0* FILE BIOTECHNO
- 0* FILE CEABA-VTB
- 0* FILE CIN
- 0* FILE ESBIOBASE
- 0* FILE FEDRIP
- 0* FILE FOMAD
- 0* FILE FOREGE
- 0* FILE FROSTI
- O+ DILE DOMA
- 0* FILE FSTA
- 1 FILE IFIPAT
- 0* FILE KOSMET
- 0* FILE MEDICONF
- 0* FILE NTIS
- 0* FILE NUTRACEUT
- 0* FILE PASCAL
- 0* FILE PHARMAML
- 2 FILE USPATFULL
- 1 FILE WPIDS
- 1 FILE WPINDEX

QUE IMMUNOPHILIN(P) CYTOPLASM(P) 8.4

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, ...' ENTERED AT 13:30:21 ON 17 NOV 2003

SEA IMMUNOPHIL?

15 FILE ADISCTI

- 5 FILE ADISINSIGHT
- 5 FILE ADISNEWS
- 29 FILE AGRICOLA
 - 5 FILE ANABSTR
- 2 FILE AQUASCI
- 18 FILE BIOBUSINESS
- 11 FILE BIOCOMMERCE
- 772 FILE BIOSIS

- 17 FILE BIOTECHABS
- 17 FILE BIOTECHDS

SEA IMMUNOPHILIN

- 8 FILE ADISCTI
- 2 FILE ADISINSIGHT
- 4 FILE ADISNEWS
- 22 FILE AGRICOLA
- 2 FILE ANABSTR
- 1 FILE AQUASCI
- 10 FILE BIOBUSINESS
- 7 FILE BIOCOMMERCE
- 632 FILE BIOSIS
- 15 FILE BIOTECHABS
- 15 FILE BIOTECHDS
- 322 FILE BIOTECHNO
- 24 FILE CABA
- 105 FILE CANCERLIT
- 698 FILE CAPLUS
 - 4 FILE CEABA-VTB
- 14 FILE CEN
- 4 FILE CIN
- 14 FILE CONFSCI
- 36 FILE DISSABS
- 95 FILE DDFU
- 298 FILE DGENE
 - 2 FILE DRUGNL
- 121 FILE DRUGU
 - 1 FILE DRUGUPDATES
 - 5 FILE EMBAL
- 622 FILE EMBASE
- 333 FILE ESBIOBASE
- 15 FILE FEDRIP
- 2 FILE FSTA
- 853 FILE GENBANK
- 137 FILE IFIPAT
- 32 FILE JICST-EPLUS
- 208 FILE LIFESCI
- 433 FILE MEDLINE
 - 5 FILE NTIS
- 161 FILE PASCAL
 - 2 FILE PHAR
 - 1 FILE PHARMAML
 - 7 FILE PHIN
- 19 FILE PROMT

```
=> s mqifvktltqktitlevepsdti/sqsp
                                              328 MQIFVKTLTGKTITLEVEPSDTI/SQSP
\Rightarrow s 11 and sq1<50-
NUMERIC VALUE NOT VALID '50-'
Numeric values may contain 1-8 significant figures. If range notation
 is used, both the beginning and the end of the range must be
 specified, e.g., '250-300/MW'. Expressions such as '250-/MW' are not
 allowed. To search for values above or below a given number, use the
>, =>, <, or <= operators, e.g., 'MW => 250'. Text terms cannot be
used in numeric expressions. If you specify a unit, it must be
dimensionally correct for that field code. To see the unit
 designations for field codes in the current file, enter "DISPLAY UNIT
ALL" at an arrow prompt (=>).
 => s 11 and sql<50
                             3358574 SQL<50
                                                      9 L1 AND SQL<50
L2
 => d sqide 1-
 YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y
                     ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
 1.2
                     600695-88-3 REGISTRY
RN
                     Glycine, L-methionyl-L-glutaminyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-
 CN
                     lysyl-L-threonyl-L-leucyl-L-threonylglycyl-L-lysyl-L-threonyl-L-isoleucyl-
                     \verb|L-threonyl-L-leucyl-L-.alpha.-glutamyl-L-valyl-L-.alpha.-glutamyl-L-prolyl-leucyl-L-.alpha.-glutamyl-L-prolyl-leucyl-L-.alpha.-glutamyl-L-prolyl-leucyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.alpha.-glutamyl--.al
                     L-seryl-L-.alpha.-aspartyl-L-threonyl-L-isoleucyl-L-.alpha.-glutamyl-L-
                     as paraginyl-L-valyl-L-lysyl-L-alanyl-L-lysyl-L-isoleucyl-L-glutaminyl-L-alanyl-L-isoleucyl-L-glutaminyl-L-alanyl-L-alanyl-L-isoleucyl-L-glutaminyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alan
                      .alpha.-aspartyl-L-lysyl-L-.alpha.-qlutamylqlycyl-L-isoleucyl-L-prolyl-L-
                     prolyl-L-.alpha.-aspartyl-L-glutaminyl-L-glutaminyl-L-arginyl-L-leucyl-L-
                     isoleucyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:---
                     1-47-Ubiquitin (Theragra chalcogramms)
 CN
                     PROTEIN SEQUENCE
 FS
 SQL
                  47
                                      1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAG
 SEQ
                                              1-23
HITS AT:
                     C234 H388 N60 O73 S
MF
 CI
                    MAN
 SR
                     CA
 LC
                     STN Files:
                                                                          CA, CAPLUS
                                                               1 REFERENCES IN FILE CA (1907 TO DATE)
                                                               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
                     ANSWER 2 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
 L2
 RN
                     600695-67-8 REGISTRY
                     Glycine, L-methionyl-L-glutaminyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-
 CN
                     {\tt lysyl-L-threonyl-L-leucyl-L-threonylglycyl-L-lysyl-L-threonyl-L-isoleucyl-L-threonyl-L-isoleucyl-L-threonyl-L-isoleucyl-L-threonyl-L-isoleucyl-L-threonyl-L-isoleucyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-threonyl-L-thr
                     L-threonyl-L-leucyl-L-.alpha.-glutamyl-L-valyl-L-.alpha.-glutamyl-L-prolyl-
                     \verb|L-seryl-L-alpha.-aspartyl-L-threonyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-isoleucyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glutamyl-L-alpha.-glut
                     asparaginyl-L-valyl-L-lysyl-L-alanyl-L-lysyl-L-isoleucyl-L-glutaminyl-L-
                      .alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamylglycyl-L-isoleucyl-L-
                     prolyl-L-prolyl-L-.alpha.-aspartyl-L-glutaminyl-L-glutaminyl-L-arginyl-L-
                     leucyl-L-isoleucyl-L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
                     1-47-Ubiquitin-like protein (Theragra chalcogramms)
                     PROTEIN SEQUENCE
 FS
```

```
SQL
         1 MOIFVKTLTG KTITLEVEPS DTIENVKAKI QDFEGIPPDQ QRLIFAG
SEO
           _____ ====
HITS AT:
           1-23
     C237 H385 N59 O73 S
MF
CI
    MAN
SR
     CA
     STN Files:
                 CA, CAPLUS
LC
               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
     ANSWER 3 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
L2
     487523-03-5 REGISTRY
RN
     GenBank CAA03216 (9CI) (CA INDEX NAME)
CN
OTHER NAMES:
     GenBank CAA03216 (Translated from: GenBank A50296)
CN
     PROTEIN SEQUENCE
FS
SQL
    37
         1 SGMQIFVKTL TGKTITLEVE PSDTIENVKA KIQDKEG
SEQ
             _____ __ ___ ___
HITS AT:
           3 - 25
MF
     Unspecified
     MAN
CI
SR
     GenBank
     ANSWER 4 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
L2
     481136-72-5 REGISTRY
RN
     GenBank BAB79490 (9CI) (CA INDEX NAME)
CN
OTHER NAMES:
     GenBank BAB79490 (Translated from: GenBank AB062071)
CN
FS
     PROTEIN SEQUENCE
SQL
    34
         1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKE
SEQ
          _____ ===
           1-23
HITS AT:
     Unspecified
MF
     MAN
CI
SR
     GenBank.
     ANSWER 5 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
     442852-24-6 REGISTRY
RN
     L-Asparagine, L-seryl-L-alanyl-L-seryl-L-histidyl-L-methionyl-L-
CN
     glutaminyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-lysyl-L-threonyl-L-leucyl-
     L-threonylglycyl-L-lysyl-L-threonyl-L-isoleucyl-L-threonyl-L-leucyl-L-
     .alpha.-glutamyl-L-valyl-L-.alpha.-glutamyl-L-prolyl-L-seryl-L-.alpha.-
     aspartyl-L-threonyl-L-isoleucyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
     13: PN: WO02057462 PAGE: 14 unclaimed sequence
CN
FS
     PROTEIN SEQUENCE; STEREOSEARCH
SQL 30
PATENT ANNOTATIONS (PNTE):
Sequence | Patent
Source
        |Reference
=======+==========
Not Given|W02002057462
         lunclaimed
         |PAGE 14
```

SEQ 1 SASSHMQIFV KTLTGKTITL EVEPSDTIEN

HITS AT: 6-28

MF C142 H234 N36 O50 S

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A

$$H_{2N}$$
 H_{2N}
 H

PAGE 1-B

PAGE 1-D

PAGE 2-A
CO2H

H₂N

PAGE 2-C

PAGE 2-D

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN

RN 438449-82-2 REGISTRY

CN L-Isoleucine, L-methionyl-L-glutaminyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-lysyl-L-threonyl-L-leucyl-L-threonylglycyl-L-lysyl-L-threonyl-L-isoleucyl-L-threonyl-L-leucyl-L-alpha.-glutamyl-L-valyl-L-alpha.-glutamyl-L-prolyl-L-seryl-L-alpha.-aspartyl-L-threonyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: US6410340 SEQID: 1 claimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 23

PATENT ANNOTATIONS (PNTE):

SEQ 1 MQIFVKTLTG KTITLEVEPS DTI

HITS AT: 1-23

MF C115 H194 N26 O37 S

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 2-A

PAGE 3-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN

RN 287398-39-4 REGISTRY

L-Isoleucine, L-methionyl-L-glutaminyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-lysyl-L-threonyl-L-leucyl-L-threonylglycyl-L-lysyl-L-threonyl-L-isoleucyl-L-threonyl-L-alpha.-glutamyl-L-valyl-L-alpha.-glutamyl-L-prolyl-L-seryl-L-alpha.-aspartyl-L-threonyl-L-isoleucyl-L-alpha.-glutamyl-L-asparaginyl-L-valyl-L-lysyl-L-alanyl-L-lysyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Protein PK21 (Penaeus vannamei sinus gland N-terminal fragment)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 30

SEQ 1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI

HITS AT: 1-23

MF C150 H256 N36 O47 S

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 2-B

PAGE 3-B

PAGE 3-C

__ SMe

- 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
- L2 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
- RN 229980-78-3 REGISTRY
- CN L-Aspartic acid, L-methionyl-L-glutaminyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-lysyl-L-threonyl-L-leucyl-L-threonylglycyl-L-lysyl-L-threonyl-L-isoleucyl-L-threonyl-L-alpha.-glutamyl-L-valyl-L-alpha.-glutamyl-L-prolyl-L-seryl-L-alpha.-aspartyl-L-threonyl-L-isoleucyl-L-

.alpha.-glutamyl-L-asparaginyl-L-valyl-L-lysyl-L-alanyl-L-lysyl-L-isoleucyl-L-glutaminyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 32

SEQ 1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI QD

HITS AT: 1-23

MF C159 H269 N39 O52 S

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

1 REFERENCES IN FILE CA (1907 TO DATE) 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

NTE modified (modifications unspecified)

ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN L2 140207-70-1 REGISTRY RN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-L-glutaminyl-L-CN isoleucyl-L-phenylalanyl-L-valyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-O-(1,1-dimethylethyl)-L-threonyl-L-leucyl-O-(1,1-dimethylethyl)-Lthreonylglycyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-O-(1,1dimethylethyl)-L-threonyl-L-isoleucyl-O-(1,1-dimethylethyl)-L-threonyl-Lleucyl-L-.alpha.-glutamyl-L-valyl-L-.alpha.-glutamyl-L-prolyl-O-(1,1dimethylethyl)-L-seryl-L-.alpha.-aspartyl-O-(1,1-dimethylethyl)-L-threonyl-L-isoleucyl-L-.alpha.-glutamyl-L-asparaginyl-L-valyl-N6-[(1,1dimethylethoxy)carbonyl]-L-lysyl-L-alanyl-N6-[(1,1dimethylethoxy)carbonyl]-L-lysyl-L-isoleucyl-L-glutaminyl-L-.alpha.aspartyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-.alpha.-glutamyl-, 16,18,21,24,32,34-hexakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME) PROTEIN SEQUENCE FS SQL

1 MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEG SEQ

1-23 HITS AT:

C250 H435 N43 O69 S MF

CI MAN

SR CA

LC

STN Files: CA, CAPLUS
1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
2003:449504 CAPLUS
AN
DN
      139:258282
      Structure analysis of ubiquitin from Theragra chalcogramms egg
ΤI
      Wu, Huijian; Nose, Takeru; Noda, Kosaku; Shimohigashi, Yasuyuki
ΑU
      Department of Chemistry, Faculty and Graduate School of Sciences, Kyushu
CS
      University, Fukuoka, 812-8581, Japan
      Peptide Science (2003), Volume Date 2002, 39th, 195-198
SO
      CODEN: PSCIFQ; ISSN: 1344-7661
PΒ
      Japanese Peptide Society
      Journal
DΤ
      English
LA
                THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
                       583867-39-4P
                                        600695-23-6P 600695-67-8P
TΥ
      583867-38-3P
      600695-88-3P
      RL: BSU (Biological study, unclassified); PRP (Properties); PUR
      (Purification or recovery); BIOL (Biological study); PREP (Preparation)
          (amino acid sequence; structure anal. of ubiquitin and vitellogenin
         from Alaska pollack egg)
      ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
L3
      2002:555663 CAPLUS
AN
DN
      137:104788
      Labile fusion proteins for the introduction of foreign proteins into a
TΙ
      cell membrane
IN
      Michel, Denis
PA
      Universite de Rennes, Fr.
SO
      PCT Int. Appl., 30 pp.
      CODEN: PIXXD2
DT
      Patent
      French
LΑ
FAN.CNT 1
                                                APPLICATION NO. DATE
      PATENT NO.
                         KIND
                                DATE
                         ____
      WO 2002057462
                                20020725
                                                 WO 2002-FR217
                                                                     20020118
                          A1
PΙ
              AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
               TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
               CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                                   20010119
                                                 FR 2001-773
                                20020726
      FR 2819811
                          Α1
                                                                    20020118
                                                 EP 2002-712014
      EP 1352071
                          A1
                                20031015
               AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI FR 2001-773
                          Α
                                20010119
      WO 2002-FR217
                          W
                                20020118
RE.CNT 5
                THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
TΨ
      151336-46-8
                      191936-91-1
                                      287379-76-4
                                                      442852-20-2
                                                                      442852-21-3
      442852-22-4
                      442852-23-5 442852-24-6
                                                    442852-25-7
      442852-26-8
      RL: PRP (Properties)
          (unclaimed sequence; labile fusion proteins for the introduction of
         foreign proteins into a cell membrane)
```

ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

L3

```
ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
L3
     2002:483028 CAPLUS
ΑN
DN
     137:41739
     Use of an 8.4 kDa protein as an immunophilin reagent in protein binding
TΙ
     assays for immunosuppressive drugs
     Soldin, Steven J.
IN
     Children's Research Institute, USA
PA
SO
     U.S., 16 pp.
     CODEN: USXXAM
DТ
     Patent
     English
LΑ
FAN.CNT 1
                      KIND DATE
     PATENT NO.
                                           APPLICATION NO. DATE
                      ____
                                           _____
                      B1 20020625
                                           US 2000-643723
                                                            20000823
ΡI
     US 6410340
     US 2003082829
                      A1
                            20030501
                                           US 2002-73334
                                                            20020213
PRAI US 2000-643723 A3
                           20000823
              THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 4
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
ΙT
     438449-82-2
     RL: PRP (Properties)
         (immunophilin protein as reagent in protein binding assays for
        immunosuppressive drugs)
     ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
L3
AN
     2000:345417 CAPLUS
                                                      april /2000
DN
     133:146530
     Primary structure of CHH/MIH/GIH-like peptides in sinus gland extracts
TТ
     from Penaeus vannamei
     Wang, Y. J.; Hayes, T. K.; Holman, G. M.; Chavez, A. R.; Keeley, L. L.
ΑU
     Department of Entomology, Texas A&M University, College Station, TX,
CS
     77843-2475, USA
SO
     Peptides (New York) (2000), 21(4), 477-484
     CODEN: PPTDD5; ISSN: 0196-9781
_PB___Elsevier_Science_Inc.____
DT
     Journal
LΑ
     English
IT
                   287417-48-5 287478-97-1 287478-98-2
     287398-39-4
     287478-99-3
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (amino acid sequence; primary structure of CHH/MIH/GIH-like peptides in
        sinus gland exts. from Penaeus vannamei)
L3
     ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN
     1999:290400 CAPLUS
DN
     131:85917
ΤI
     Proteolytic degradation of hemoglobin in erythrocytes yields biologically

    active peptides

     Karelin, A. A.; Filippova, M. M.; Yatskin, O. N.; Blishchenko, E. Yu.;
ΑU
     Nazimov, I. V.; Ivanov, V. T.
     Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy
CS
     of Sciences, Moscow, 117871, Russia
     Bioorganicheskaya Khimiya (1998), 24(4), 271-281
SO
     CODEN: BIKHD7; ISSN: 0132-3423
PB
     MAIK Nauka
DT
     Journal
LA
     Russian
ΤT
     34027-29-7
                 83759-54-0 93265-50-0 138472-07-8 152685-85-3
     164984-77-4
                 164984-78-5 164984-79-6 164984-80-9 164984-81-0
     164984-82-1
                   174451-82-2
                                 183014-26-8
                                               193904-30-2
                                                             201854-01-5
     229980-61-4
                   229980-62-5
                                 229980-63-6
                                             229980-64-7
                                                             229980-65-8
```

```
229980-69-2
                                                        229980-70-5
229980-66-9
              229980-67-0
                            229980-68-1
              229980-76-1 229980-78-3 229980-80-7
229980-73-8
                                                        229980-91-0
                            229980-87-4
                                          229980-89-6
229980-83-0 .229980-85-2
                                                        229981-03-7
                            229980-97-6
                                          229981-01-5
229980-92-1
              229980-94-3
                                                        229981-16-2
229981-06-0
              229981-08-2
                            229981-11-7
                                          229981-14-0
              229981-20-8
                            229981-22-0
                                          229981-24-2
                                                        229981-27-5
229981-19-5
229981-30-0
              229981-35-5
                            229981-38-8
                                          229981-40-2
                                                        229981-43-5
                                          230284-20-5
                                                        230284-21-6
230284-17-0
              230284-18-1
                            230284-19-2
              230284-23-8
                            230284-24-9
                                          230284-25-0
                                                        230284-27-2
230284-22-7
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
study, unclassified); MFM (Metabolic formation); PRP (Properties); BIOL
(Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence);
PROC (Process)
   (proteolytic degrdn. of Hb in erythrocytes yields biol. active
   peptides)
ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
1992:174736 CAPLUS
116:174736
Solid phase peptide synthesis: fluoride ion release of protected peptide
fragments
Ramage, Robert; Barron, Christine A.; Bielecki, Stanislaw; Holden, Robert;
Thomas, David W.
Dep. Chem., Univ. Edinburgh, Edinburgh, EH9 3JJ, UK
Tetrahedron (1992), 48(3), 499-514
CODEN: TETRAB; ISSN: 0040-4020
Journal
English
114671-20-4P 140207-70-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
```

(prepn. of, by solid-phase method with (hydroxymethylphenyl)trimethylsi

L3

AN

DN

TI

ΑU

CS

SO

DT

LΑ

IT

lylpropanoate handle)